Talaris Therapeutics Announces Closing of Initial Public Offering
May 11 2021 - 4:01PM
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage
cell therapy company developing therapies with the potential to
transform the standard of care in solid organ transplantation,
certain severe autoimmune diseases, and certain severe
non-malignant blood, immune and metabolic disorders, today
announced the closing of its initial public offering of 8,825,000
shares of its common stock at a price to the public of $17.00 per
share. The gross proceeds of the offering were approximately $150.0
million, before deducting underwriting discounts and commissions
and other offering expenses. The shares began trading on the Nasdaq
Global Market on May 7, 2021 under the symbol “TALS.” All shares in
the offering were offered by Talaris Therapeutics. In addition, the
underwriters have a 30-day option to purchase up to an additional
1,323,750 shares of common stock at the initial public offering
price less underwriting discounts and commissions.
Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim
Securities are acting as joint book-running managers for the
offering.
A registration statement relating to these securities has been
filed and was declared effective by the Securities and Exchange
Commission on May 6, 2021. This offering was made only by means of
a written prospectus. Copies of the final prospectus relating to
the initial public offering can be obtained, when available, from:
Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180
Varick Street, 2nd Floor, New York, NY 10014; SVB Leerink LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110, by telephone at (800) 808-7525, ext. 6105, or by
email at syndicate@svbleerink.com; Evercore Group L.L.C.,
Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor,
New York, NY 10055, or by telephone at (888) 474-0200, or by email
at ecm.prospectus@evercore.com; and Guggenheim Securities, LLC,
Attention: Equity Syndicate Department, 330 Madison Avenue, New
York, NY 10017, by telephone at (212) 518-5548, or by email at
GSEquityProspectusDelivery@guggenheimpartners.com.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor will there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation, or sale would be unlawful before
registration or qualification under the securities laws of that
state or jurisdiction.
About Talaris
Therapeutics
Talaris Therapeutics, Inc. is a
late-clinical stage cell therapy company developing an innovative
method of allogeneic hematopoietic stem cell transplantation with
the potential to transform the standard of care in solid organ
transplantation, certain severe autoimmune diseases, and certain
severe non-malignant blood, immune and metabolic disorders. Talaris
maintains corporate offices in Boston, Mass., and its cell
processing facility in Louisville, Ky.
Media Contact:
Lisa RaffenspergerTen Bridge
Communicationslisa@tenbridgecommunications.com (617)
903-8783
Talaris Therapeutics (NASDAQ:TALS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Talaris Therapeutics (NASDAQ:TALS)
Historical Stock Chart
From Apr 2023 to Apr 2024